Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3 Alpha Hydroxy 5 Alpha Pregnan 20 One
2. 3 Alpha Hydroxy 5 Beta Pregnan 20 One
3. 3 Alpha, 5 Beta Tetrahydroprogesterone
4. 3 Alpha, 5 Beta-tetrahydroprogesterone
5. 3 Alpha-hydroxy-5 Alpha-pregnan-20-one
6. 3 Alpha-hydroxy-5 Beta-pregnan-20-one
7. 3 Hydroxypregnan 20 One
8. 3-hydroxypregnan-20-one
9. 3beta Hydroxy 5alpha Pregnan 20 One
10. 3beta-hydroxy-5alpha-pregnan-20-one
11. Allopregnan 3 Beta Ol 20 One
12. Allopregnan-3 Beta-ol-20-one
13. Allopregnanolone
14. Alpha-hydroxy-5 Alpha-pregnan-20-one, 3
15. Alpha-hydroxy-5 Beta-pregnan-20-one, 3
16. Alpha-pregnan-20-one, 3 Alpha-hydroxy-5
17. Beta-ol-20-one, Allopregnan-3
18. Beta-pregnan-20-one, 3 Alpha-hydroxy-5
19. Eltanolone
20. Epipregnanolone
21. Pregnan 3alpha Ol 20 One
22. Pregnan-3alpha-ol-20-one
23. Pregnanolone, (3alpha)-isomer
24. Pregnanolone, (3alpha, 5beta, 17-alpha)-isomer
25. Pregnanolone, (3alpha,5alpha)-isomer
26. Pregnanolone, (3alpha,5beta)-isomer
27. Pregnanolone, (3beta)-isomer
28. Pregnanolone, (3beta, 5alpha)-isomer
29. Pregnanolone, (3beta, 5alpha, 17alpha)-isomer
30. Pregnanolone, (3beta, 5alpha, 8alpha, 17beta)-isomer
31. Pregnanolone, (3beta, 5beta)-isomer
32. Pregnanolone, (3beta, 5beta, 17alpha)-isomer
33. Pregnanolone, (3beta, 5beta,14beta)-isomer
34. Pregnanolone, (5alpha)-isomer
35. Sepranolone
1. Eltanolone
2. 128-20-1
3. 3alpha-hydroxy-5beta-pregnan-20-one
4. Pregnan-3alpha-ol-20-one
5. Pregnanolone Ii
6. Eltanolona
7. Eltanolonum
8. Eltanolone [inn]
9. Skf 6455
10. Allopregnanolone
11. Nsc 82867
12. 5beta-pregnan-3alpha-ol-20-one
13. (3alpha,5beta)-3-hydroxypregnan-20-one
14. Kabi 2213
15. Kabi-2213
16. 3alpha-hydroxy-5beta-pregnane-20-one
17. Pregnan-20-one, 3-hydroxy-, (3alpha,5beta)-
18. Pregnan-3.alpha.-ol-20-one
19. Nsc-82867
20. Bxo86p3xxw
21. 3.alpha.-hydroxy-5.beta.-pregnan-20-one
22. Chebi:1712
23. 5.beta.-pregnan-20-one, 3.alpha.-hydroxy-
24. Skf-6455
25. 1-[(3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone
26. 3.alpha.,5.beta.-epimeric Pregnanolone
27. 3.alpha.-hydroxy-5.beta.-tetrahydroprogesterone
28. Pregnan-20-one, 3-hydroxy-, (3.alpha.,5.beta.)-
29. Eltanolonum [inn-latin]
30. Eltanolona [inn-spanish]
31. 1-((3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethan-1-one
32. Allopregnan-3 Beta-ol-20-one
33. 3alpha-hydroxy-5beta-tetrahydroprogesterone
34. 3alpha,5beta-epimeric Pregnanolone
35. Pregnan-3a-ol-20-one
36. Mls002694512
37. Unii-bxo86p3xxw
38. Pregnanolone, (3alpha,5beta)-isomer
39. 3 Hydroxypregnan 20 One
40. Pregnan 3alpha Ol 20 One
41. 3 Alpha, 5 Beta-tetrahydroprogesterone
42. Brn 4785659
43. 3 Alpha-hydroxy-5 Beta-pregnan-20-one
44. 3-alpha-hydroxy-5-beta-pregnan-20-one
45. 3 Alpha-hydroxy-5 Alpha-pregnan-20-one
46. Pregnanolone, (3beta)-isomer
47. Pregnanolone, (3alpha)-isomer
48. Pregnanolone, (5alpha)-isomer
49. Allopregnan 3 Beta Ol 20 One
50. Beta-ol-20-one, Allopregnan-3
51. (3?,5?)-3-hydroxy-pregnan-20-one
52. 3alpha,5beta-thp
53. 3beta Hydroxy 5alpha Pregnan 20 One
54. Pregnanolone, (3alpha,5alpha)-isomer
55. Pregnanolone, (3beta, 5beta)-isomer
56. Pregnanolone, (3beta, 5alpha)-isomer
57. 3 Alpha, 5 Beta Tetrahydroprogesterone
58. Wln: L E5 B666tj A1 E1 Fv1 Oq
59. 3 Alpha Hydroxy 5 Beta Pregnan 20 One
60. 5beta-pregnan-20-one, 3alpha-hydroxy-
61. 3 Alpha Hydroxy 5 Alpha Pregnan 20 One
62. Alpha-hydroxy-5 Beta-pregnan-20-one, 3
63. Beta-pregnan-20-one, 3 Alpha-hydroxy-5
64. 5-beta-pregnan-20-one, 3-alpha-hydroxy-
65. Alpha-hydroxy-5 Alpha-pregnan-20-one, 3
66. Alpha-pregnan-20-one, 3 Alpha-hydroxy-5
67. Kabi2213
68. Pregnan-20-one, 3-hydroxy-, (3a,5b)-
69. Pregnanolone, (3beta, 5beta,14beta)-isomer
70. Pregnanolone, (3beta, 5beta, 17alpha)-isomer
71. Eltanolone [mart.]
72. Pregnanolone, (3beta, 5alpha, 17alpha)-isomer
73. Pregnanolone, (3alpha, 5beta, 17-alpha)-isomer
74. Schembl56664
75. 3-hydroxy-5-pregnan-20-one
76. 5?-pregnan-3?-ol-20-one
77. Chembl210952
78. 3.alpha.,5.beta.-pregnanolone
79. 3a-hydroxy-5b-pregnan-20-one
80. Dtxsid1046342
81. Pregnanolone, (3beta, 5alpha, 8alpha, 17beta)-isomer
82. Gtpl11534
83. Skf6455
84. 3alpha,5beta-tetrahydroprogesterone
85. Nsc82867
86. Zinc3800039
87. (3a,5b)-3-hydroxypregnan-20-one
88. Lmst02030175
89. Db12308
90. 5 Beta -pregnan-3 Alpha -ol-20-one
91. 5.beta.-pregnan-3.alpha.-ol-20-one
92. Pregnan-20-one, (3.alpha.,5.beta.)-
93. (3alpha,5beta)-3-hydroxy-pregnan-20-one
94. Pregnan-3.alpha.-ol-20-one [mi]
95. B7455
96. C05480
97. 128p201
98. 3-hydroxypregnan-20-one, (3.alpha.,5.beta.)-
99. J-005571
100. Q18344323
101. 1-((3r,5r,8r,9s,10s,13s,14s,17s)-3-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
102. 110350-90-8
103. P9n
| Molecular Weight | 318.5 g/mol |
|---|---|
| Molecular Formula | C21H34O2 |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 1 |
| Exact Mass | 318.255880323 g/mol |
| Monoisotopic Mass | 318.255880323 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of postpartum depression
Anesthetics
Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)
API SUPPLIERS
NDC Package Code : 60722-3011
Start Marketing Date : 2021-07-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 60722-3011
Start Marketing Date : 2021-07-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Neurology Brand Name: Isoallopregnanolone
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Relmada Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 06, 2025
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Relmada Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Relmada Acquires Tourette Therapy from Asarina Pharma
Details : Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.
Product Name : Isoallopregnanolone
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 06, 2025
Details:
Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines, including SPT-300 (glyph allopregnanolone), an oral prodrug of allopregnanolone.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: General Atlantic
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 21, 2024
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : General Atlantic
Deal Size : $225.0 million
Deal Type : Series B Financing
Seaport Therapeutics Closes $225M Series B Financing Round
Details : Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines, including SPT-300 (glyph allopregnanolone), an oral prodrug of allopregnanolone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2024
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2023
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2023
Details:
The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: US Department of Defense
Deal Size: $11.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 01, 2023
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : US Department of Defense
Deal Size : $11.4 million
Deal Type : Funding
Details : The funding will advance Phase 2 trial of company's therapeutic candidate, LYT-300, an oral prodrug of allopregnanolone, for the treatment of Fragile X-associated Tremor Ataxia Syndrome (FXTAS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 01, 2023
Details:
LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2023
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone prodrug) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatme...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2023
Details:
LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2023
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (allopregnanolone) is a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions. It is be developed for anxiety and postpartum depression treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 14, 2023
Details:
LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopregnanolone.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2022
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and G...
Details : LYT-300 is a clinical therapeutic candidate that is in development as a potenƟal treatment for a range of neurological and neuropsychological condions. Developed using PureTech's Glyph™ technology plaƞorm, LYT-300 is an oral prodrug of natural allopr...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2022
Details:
Sepranolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tourette Syndrome.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2022
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
Details : Sepranolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2022
Details:
LYT-300 is an oral prodrug of natural allopregnanolone candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions. Developed using PureTech's Glyph technology platform.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 14, 2022
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 is an oral prodrug of natural allopregnanolone candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions. Developed using PureTech's Glyph technology platform.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2022
Details:
LYT-300 (Oral Allopregnanolone), is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline.
Lead Product(s): Allopregnanolone,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2021
Lead Product(s) : Allopregnanolone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYT-300 (Oral Allopregnanolone), is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
APIs
Reply
20 Feb 2026
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
85
PharmaCompass offers a list of Allopregnanolone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Allopregnanolone manufacturer or Allopregnanolone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Allopregnanolone manufacturer or Allopregnanolone supplier.
A Allopregnanolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Allopregnanolone, including repackagers and relabelers. The FDA regulates Allopregnanolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Allopregnanolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Allopregnanolone supplier is an individual or a company that provides Allopregnanolone active pharmaceutical ingredient (API) or Allopregnanolone finished formulations upon request. The Allopregnanolone suppliers may include Allopregnanolone API manufacturers, exporters, distributors and traders.
click here to find a list of Allopregnanolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Allopregnanolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Allopregnanolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Allopregnanolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Allopregnanolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Allopregnanolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Allopregnanolone suppliers with NDC on PharmaCompass.
Allopregnanolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Allopregnanolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Allopregnanolone GMP manufacturer or Allopregnanolone GMP API supplier for your needs.
A Allopregnanolone CoA (Certificate of Analysis) is a formal document that attests to Allopregnanolone's compliance with Allopregnanolone specifications and serves as a tool for batch-level quality control.
Allopregnanolone CoA mostly includes findings from lab analyses of a specific batch. For each Allopregnanolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Allopregnanolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Allopregnanolone EP), Allopregnanolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Allopregnanolone USP).
Comment (9)
